Vibrato

Vibrato Medical Announces Positive Results for Early Feasibility Study of Wearable, Non-Invasive Therapeutic Ultrasound to Treat Chronic Limb-Threatening Ischemia (CLTI)

Retrieved on: 
Wednesday, November 1, 2023
Health, Medical Devices, Radiology, Clinical Trials, Research, Science, Cardiology, Blood vessel, TUS, Patient, Heart, Chronic limb threatening ischemia, Medicine, Vasodilation, CLTI, Perfusion, Vibrato, Ischemia, Claudication, Moyamoya disease, Disease, Orange County, VIVA, Amputation, PAD, Perception, Wynn Las Vegas, Prelude, Medical imaging, Pharmaceutical industry, MD

Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chronic Limb-Threatening Ischemia (CLTI) has successfully met its endpoint.

Key Points: 
  • Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that data from an early feasibility study of Non-Invasive Therapeutic Ultrasound (TUS) to treat Chronic Limb-Threatening Ischemia (CLTI) has successfully met its endpoint.
  • The study evaluated patients with infrapopliteal PAD and measured changes in foot perfusion and oxygenation as well as therapy tolerance, compliance and perception.
  • Patients in the trial had Rutherford class 3, 4 or 5 PAD, meaning severe claudication, ischemic rest pain or tissue loss including nonhealing ulcers.
  • “These early findings are promising for the future of non-invasive therapeutic options to treat chronic limb-threatening ischemia,” said Juliana Elstad, CEO at Vibrato.

First Round of Late-Breaking Clinical Trial Results Announced at VIVA23

Retrieved on: 
Tuesday, October 31, 2023
Atheroma, Peripheral artery disease, Diabetes, Pivotal trial, Ulcer, Transducer, Male, Disease, PAP, Buerger's test, Classification, The Unreconstructed M, IVUS, Amputation, Stent, PAD, PP, Thorpe tube flowmeter, TUS, Calf, Chin Na, Vein, Telephone, TASC, Bare, Vibrato, Life, SP, W. L. Gore & Associates, VIVA, Safety, Patient, Dyslipidemia, Blood vessel, Plaque, History, CLTI, Coronary artery disease, Perfusion, Restenosis, Research, Foot, Spur, Atherectomy, Șaeș, Artery, Education, DCB, Doppler effect, Dialysis, Hypertension, FP, Freedom, Wynn Las Vegas, Wound healing, Medical imaging, Pharmaceutical industry, Birth control, Surveying, Medtronic

Below are highlights of this morning's 5 late-breaking clinical trial presentations.

Key Points: 
  • Below are highlights of this morning's 5 late-breaking clinical trial presentations.
  • At 20 centers without roll-ins across the United States, 105 no-option CLTI patients were enrolled in a nonrandomized manner.
  • The median age was 70 years, two-thirds of the patients were male, and one-quarter of patients were Hispanic or Latino.
  • 1-Year Results of the DEEPER OUS Trial: The Bare Temporary Spur Stent System in Combination With a Paclitaxel-Coated Balloon
    The DEEPER OUS trial is a prospective, nonrandomized, multicenter, single-arm trial taking place in New Zealand, Germany, and Switzerland.

Vibrato leads the charge to make it easier for the self-employed to get mortgages

Retrieved on: 
Tuesday, December 13, 2022
American Dream, W-2, Workforce, Direct-to-consumer advertising, Marketing, Tufting, Entrepreneurship, Acquisition, Real estate, PHOENIX, Vibrato

PHOENIX, Dec. 13, 2022 /PRNewswire/ -- Buying a home is part of the American Dream. However, achieving that vision can be challenging. Self-employment and entrepreneurship can add obstacles when trying to get a home.

Key Points: 
  • This is a challenge that is only growing with a rapid growth rate within the workforce now identifying as self-employed.
  • The founders of Vibrato understand that as the workforce changes and becomes more unique, so must the mortgage lending process.
  • Vibrato, a mortgage lender based in Phoenix, is uniquely set up to help self-employed Arizona residents find the perfect home from which tocontinue their work.
  • Utilizing bank statements over tax returns ensures that deductions don't kill a self-employed individual's chances of qualifying for a mortgage.

Vibrato Medical Appoints Paul A. LaViolette to its Board of Directors

Retrieved on: 
Thursday, November 4, 2021
Biotechnology, Health, Cardiology, Medical Devices, BSC, U.S. Venture Partners, MD, Industry, Moyamoya disease, Health, Medicine, Patient, Vibrato, Face, Boston Scientific, Vasodilation, Medtech, Perfusion, CEO, Laviolette, Partner, COO, PAD, Partner (business rank), Doctor of Philosophy, Pharmaceutical industry

Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that Paul A. LaViolette has been appointed to its board of directors.

Key Points: 
  • Vibrato Medical, an innovator in the treatment of peripheral arterial disease (PAD), announced today that Paul A. LaViolette has been appointed to its board of directors.
  • The contributions he has made to the medical technology industry have left a profound impact, said Juliana Elstad, CEO of Vibrato Medical.
  • Im so pleased to be joining the Vibrato board and to support development of this disruptive, noninvasive therapy for advanced peripheral arterial disease, said LaViolette.
  • LaViolette will join current Vibrato board members Bobby Azamian, MD, PhD, Juliana Elstad, Babak Nazer, MD, and Jason Tester.

Vibrato Medical Closes $4M Series A Funding Round and Receives $1.5M NIH Grant

Retrieved on: 
Tuesday, September 14, 2021
Health, Clinical Trials, Cardiology, Medical Devices, Heart, Stroke, CEO, CA, Technology, Health, Doctor of Philosophy, Medicine, Patient, CFO, Moyamoya disease, Amputation, Clinical trial, Veni, vidi, vici, Mortality, NIH, Risk management, Disease, Sage Group, PAD, Sores, Growth, National, Perfusion, Pain, Heart failure, Vibrato, Population, Compliance, CLI, Vasodilation, Pharmaceutical industry, Medical imaging

Our goal is to become the preferred therapeutic system for patients with reduced tissue perfusion, such as those with PAD and CLI.

Key Points: 
  • Our goal is to become the preferred therapeutic system for patients with reduced tissue perfusion, such as those with PAD and CLI.
  • Our recent funding puts us on the path towards that vision, said Juliana Elstad, CEO at Vibrato.
  • We are excited to partner with Vibrato Medical on the development of a truly novel technology to treat this terrible condition.
  • The company plans to use Series A funding and its $1.5M NIH grant for its pilot clinical study, to design and build its second-generation device, and advance its intellectual property.